Results 11 to 20 of about 47,442 (285)
EXCLI Journal : Experimental and Clinical Sciences, 2023 Amyloidosis is a protein deposition disorder in which insoluble fibril structures accumulate in the bodily tissues damaging the organ function. Cardiac amyloidosis is a severe but under-reported medical condition characterized by the accumulation of ...
Gnana Deepthi Medarametla +9 more
doaj +6 more sources
Heart Failure Clinics, 2022 Amyloid deposits are defined by their tinctorial properties. Under the light microscope amyloid deposits are eosinophilic and amorphous when stained with hematoxylin and eosin. With Congo red staining the deposits are positive and under polarized light will exhibit green birefringence.
T, Tadokoro +3 more
+6 more sources
QJM: An International Journal of Medicine, 2018 Systemic amyloidosis comprises an uncommon group of disorders caused by the extracellular deposition of misfolded proteins in various organs. Cardiac amyloid deposition, causing an infiltrative/restrictive cardiomyopathy, is a frequent feature of amyloidosis and a major determinant of survival.
C H, Yu, Y H, Lu, J H, Lu
openaire +6 more sources
Clinical Medicine, 2005 Systemic amyloidosis commonly affects the heart. Indeed, cardiac symptoms may be the first clinical indicator of underlying amyloid deposition. Using two case studies, this article reviews the latest evidence regarding cardiac amyloidosis. The diagnosis of cardiac involvement can be established through imaging with echocardiography and magnetic ...
Maredia, Neil, Ray, Simon G
openaire +4 more sources
Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation in Cardiac Amyloidosis. [PDF]
J ArrhythmLeft atrial appendage occlusion‐related outcomes in patients with amyloid cardiomyopathy. ABSTRACT Background Cardiac amyloidosis (CA) is frequently complicated by atrial fibrillation (AF), yet outcomes after left atrial appendage occlusion (LAAO) in this population remain poorly defined.
Almakadma AH +10 more
europepmc +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Background Outcomes data in patients with cardiac amyloidosis after implantable cardioverter‐defibrillator (ICD) implantation are limited. We compared outcomes of patients with ICDs implanted for cardiac amyloidosis versus nonischemic cardiomyopathies ...
Angela Y. Higgins +9 more
doaj +1 more source
Blood-based microRNA profiling in patients with cardiac amyloidosis. [PDF]
PLoS ONE, 2018 INTRODUCTION:Amyloidosis is caused by dysregulation of protein folding resulting in systemic or organ specific amyloid aggregation. When affecting the heart, amyloidosis can cause severe heart failure, which is associated with a high morbidity and ...
Anselm A Derda +8 more
doaj +1 more source
Abnormal Myocardial Blood Flow Reserve Observed in Cardiac Amyloidosis [PDF]
, 2016 We performed real-time myocardial contrast echocardiography on a patient with cardiac amyloidosis and previous normal coronary angiography presenting with atypical chest pain to assess myocardial blood flow reserve (MBFR).
Greaves, K, Nam, MC, Nel, K, Senior, R
core +1 more source
Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis
Methodist DeBakey Cardiovascular Journal, 2022 Cardiac amyloidosis is increasingly recognized as an underlying cause of left ventricular wall thickening, heart failure, and arrhythmia with variable clinical presentation.
Sajan S. Gill +4 more
doaj +1 more source
The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa [PDF]
, 2016 Transthyretin (TTR) pV142I (rs76992529-A) is one of the 113 variants in the human TTR gene associated with systemic amyloidosis. It results from a G to A transition at a CG dinucleotide in the codon for amino acid 122 of the mature protein (TTR V122I ...
Alexander, Alice A +10 more
core +1 more source